Should we follow the 9th ACCP guidelines for VTE prevention in surgical patients?

Area of Science:

• Cardiology and Thrombosis Management
• Clinical Practice Guidelines Development
• Evidence-Based Medicine

Background:

• The American College of Chest Physicians (ACCP) periodically updates its guidelines on antithrombotic therapy.
• Previous guideline editions relied on surrogate outcomes, potentially limiting clinical relevance.
• Methodological rigor and transparency in guideline development are crucial for clinical decision-making.

Purpose of the Study:

• To present the significant revisions in the 9th edition of the ACCP guidelines for antithrombotic therapy and prevention.
• To highlight methodological advancements, including the GRADE system and conflict of interest assessments.
• To detail changes in recommendations based on updated evidence and patient values.

Main Methods:

• Adoption of the GRADE methodology by chapter leadership.
• Rigorous panelist selection focusing on conflicts of interest.
• Explicit presentation of evidence through profiles and summary tables.
• Systematic review of patient values and preferences regarding thrombotic and bleeding risks.

Main Results:

• Increased emphasis on clinically relevant events over surrogate outcomes.
• Downgraded strength of most recommendations compared to previous editions.
• Upgraded recommendation for extended low molecular weight heparin (LMWH) prophylaxis post-cancer surgery.
• Introduction of aspirin as a controversial option post-hip/knee arthroplasty.
• New oral anticoagulants recommended, with LMWH preferred; extended prophylaxis duration suggested for orthopedic surgery.

Conclusions:

• The 9th ACCP guidelines reflect enhanced methodological rigor and a patient-centered approach.
• Updated recommendations aim for a better balance between therapeutic benefits and bleeding risks.
• Specific changes address prevention strategies in non-orthopedic and orthopedic surgical patients, including extended prophylaxis durations.